Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “MET Exon 14 Mutation”

31 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 31 results

Not applicableLooking for participantsNCT05703516
What this trial is testing

A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea

Who this might be right for
Non-Small-Cell Lung Carcinoma
Novartis Pharmaceuticals 44
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07153770
What this trial is testing

Bozitinib Combined With Chemotherapy as Radical Treatment for Stage IIA-IIIC MET-Altered Non-Small Cell Lung Cancer

Who this might be right for
NSCLCMET Exon 14 MutationMET Activating Mutation
Shanghai Pulmonary Hospital, Shanghai, China 34
Testing effectiveness (Phase 2)Looking for participantsNCT05800340
What this trial is testing

Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC

Who this might be right for
Non-Small Cell Lung CancerRET Driver MutationBRAF V600 Mutation+3 more
Guangdong Provincial People's Hospital 30
Not applicableEnrolling By InvitationNCT07122882
What this trial is testing

Integrated Genomics in Oncogene-driven NSCLC With Acquired Resistance

Who this might be right for
Oncogene-addicted Non Small Cell Lung CancerEGFR MutationALK Fusion-positive Solid or CNS Tumors+10 more
Chang Gung Memorial Hospital 40
Testing effectiveness (Phase 2)WithdrawnNCT03240393
What this trial is testing

Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
CarcinomaNon-Small-Cell Lung Cancer
Novartis Pharmaceuticals
Early research (Phase 1)Active Not RecruitingNCT05782361
What this trial is testing

POTENT - Tepotinib in Combination With Pembrolizumab in NSCLC

Who this might be right for
Advanced CancerNon Small Cell Lung Cancer
Institute of Cancer Research, United Kingdom 19
Large-scale testing (Phase 3)Ended earlyNCT04427072
What this trial is testing

Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Novartis Pharmaceuticals 22
Testing effectiveness (Phase 2)Looking for participantsNCT03175224
What this trial is testing

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

Who this might be right for
Solid TumorsAdvanced CancerRenal Cancer+15 more
Apollomics Inc. 497
Testing effectiveness (Phase 2)WithdrawnNCT03147976
What this trial is testing

QUILT-3.036: AMG 337 in Subjects With Advanced or Metastatic Solid Tumors

Who this might be right for
Solid Tumor
NantPharma, LLC
Testing effectiveness (Phase 2)Study completedNCT02414139
What this trial is testing

Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Novartis Pharmaceuticals 373
Large-scale testing (Phase 3)Looking for participantsNCT06988475
What this trial is testing

DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations

Who this might be right for
Solid TumourHaematological MalignancyMalignant Neoplasm+8 more
Cancer Research UK 30
Post-approval studies (Phase 4)Study completedNCT05110196
What this trial is testing

Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC.

Who this might be right for
Non-Small Cell Lung Carcinoma
Novartis Pharmaceuticals 50
Not applicableStudy completedNCT04575025
What this trial is testing

Special Drug Use-results Surveillance of Tabrecta Tablets

Who this might be right for
Non-small Cell Lung Cancer
Novartis Pharmaceuticals 109
Large-scale testing (Phase 3)Looking for participantsNCT06908993
What this trial is testing

Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated

Who this might be right for
Advanced Non Small Cell Lung CancerMET Exon 14 Mutation
Intergroupe Francophone de Cancerologie Thoracique 133
Testing effectiveness (Phase 2)Looking for participantsNCT04270591
What this trial is testing

Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer

Who this might be right for
C-Met Exon 14 Mutation
Haihe Biopharma Co., Ltd. 183
Testing effectiveness (Phase 2)WithdrawnNCT04992858
What this trial is testing

Ningetinib in Advanced NSCLC Skipping Mutations With MET Exon 14 Skipping Mutations

Who this might be right for
Advanced NSCLC
Sunshine Lake Pharma Co., Ltd.
Testing effectiveness (Phase 2)WithdrawnNCT04460729
What this trial is testing

A Phase II, Open-Label, Multicenter Study of Capmatinib in Subjects With MET Exon 14 Skipping Mutation Positive, Advanced, NSCLC With Brain Metastases

Who this might be right for
Non-small Cell Lung Carcinoma (NSCLC)
Novartis Pharmaceuticals
Not applicableStudy completedNCT06161051
What this trial is testing

Treatment Patterns and Real-World Clinical Outcomes in Patients With Advanced NSCLC and MET Exon 14 Skipping Mutation in the United States

Who this might be right for
Advanced Non-small Cell Lung Cancer and MET Exon 14 Skipping Mutation
Novartis Pharmaceuticals 287
Testing effectiveness (Phase 2)UnknownNCT04647838
What this trial is testing

Tepotinib in Solid Tumors Harboring MET Alterations

Who this might be right for
Solid TumorMET Exon 14 Skipping MutationMET Amplification
Chungbuk National University Hospital 100
Large-scale testing (Phase 3)Looking for participantsNCT05989542
What this trial is testing

A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2)

Who this might be right for
Non-small Cell Lung Cancer
Beijing Pearl Biotechnology Limited Liability Company 136
Next Page